| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Inflammatory Bowel Diseases | 17 | 2022 | 575 | 3.130 |
Why?
|
| Liver Diseases | 6 | 2024 | 242 | 2.550 |
Why?
|
| Short Bowel Syndrome | 4 | 2024 | 38 | 2.540 |
Why?
|
| Capsule Endoscopy | 4 | 2023 | 33 | 2.520 |
Why?
|
| Parenteral Nutrition | 6 | 2024 | 63 | 2.370 |
Why?
|
| Colitis, Ulcerative | 13 | 2024 | 736 | 2.350 |
Why?
|
| Gastrointestinal Agents | 5 | 2024 | 171 | 1.760 |
Why?
|
| Gastrointestinal Hemorrhage | 8 | 2023 | 237 | 1.460 |
Why?
|
| Liver | 4 | 2024 | 1205 | 1.400 |
Why?
|
| Nutrition Therapy | 2 | 2020 | 10 | 1.340 |
Why?
|
| Intestinal Diseases | 3 | 2020 | 79 | 1.340 |
Why?
|
| Crohn Disease | 9 | 2022 | 758 | 1.210 |
Why?
|
| Clostridium Infections | 6 | 2022 | 124 | 1.150 |
Why?
|
| Autoimmune Diseases | 8 | 2021 | 249 | 1.090 |
Why?
|
| Humans | 90 | 2024 | 89063 | 1.080 |
Why?
|
| Neoplasms | 7 | 2024 | 3035 | 1.030 |
Why?
|
| Biosimilar Pharmaceuticals | 4 | 2020 | 23 | 1.020 |
Why?
|
| Fish Oils | 1 | 2024 | 14 | 0.960 |
Why?
|
| Fat Emulsions, Intravenous | 1 | 2024 | 16 | 0.950 |
Why?
|
| Nutrition Assessment | 2 | 2021 | 19 | 0.920 |
Why?
|
| Rheumatic Diseases | 2 | 2021 | 26 | 0.910 |
Why?
|
| Gastroenterology | 2 | 2018 | 144 | 0.910 |
Why?
|
| Hospitalization | 8 | 2023 | 876 | 0.910 |
Why?
|
| Infliximab | 4 | 2020 | 159 | 0.870 |
Why?
|
| Peptides | 2 | 2024 | 646 | 0.860 |
Why?
|
| Anemia, Iron-Deficiency | 1 | 2023 | 20 | 0.860 |
Why?
|
| Retrospective Studies | 20 | 2024 | 9003 | 0.860 |
Why?
|
| Colitis | 3 | 2021 | 244 | 0.850 |
Why?
|
| Vaccination | 2 | 2022 | 273 | 0.850 |
Why?
|
| Enterocolitis | 1 | 2022 | 13 | 0.830 |
Why?
|
| Opportunistic Infections | 1 | 2022 | 60 | 0.810 |
Why?
|
| Peritoneal Neoplasms | 2 | 2023 | 184 | 0.810 |
Why?
|
| Intestine, Small | 3 | 2023 | 299 | 0.800 |
Why?
|
| Patient Readmission | 4 | 2024 | 351 | 0.800 |
Why?
|
| Cathartics | 1 | 2021 | 27 | 0.790 |
Why?
|
| Immune System Diseases | 2 | 2019 | 27 | 0.780 |
Why?
|
| Cytomegalovirus Infections | 1 | 2022 | 146 | 0.770 |
Why?
|
| Endoscopy, Gastrointestinal | 2 | 2021 | 157 | 0.770 |
Why?
|
| Enterocolitis, Pseudomembranous | 7 | 2015 | 52 | 0.760 |
Why?
|
| Vaccines | 1 | 2022 | 83 | 0.760 |
Why?
|
| Malnutrition | 1 | 2021 | 32 | 0.740 |
Why?
|
| Nasturtium | 1 | 2020 | 3 | 0.720 |
Why?
|
| Fasciola hepatica | 1 | 2020 | 4 | 0.720 |
Why?
|
| Antibodies, Helminth | 1 | 2020 | 10 | 0.720 |
Why?
|
| Fascioliasis | 1 | 2020 | 5 | 0.720 |
Why?
|
| Dyspepsia | 1 | 2020 | 9 | 0.720 |
Why?
|
| Neuroendocrine Tumors | 2 | 2019 | 117 | 0.700 |
Why?
|
| Angiodysplasia | 1 | 2019 | 4 | 0.690 |
Why?
|
| Eosinophilia | 1 | 2020 | 84 | 0.690 |
Why?
|
| Spiders | 1 | 2019 | 16 | 0.680 |
Why?
|
| Bone Resorption | 1 | 2019 | 42 | 0.670 |
Why?
|
| Risk Factors | 17 | 2024 | 5466 | 0.660 |
Why?
|
| Biological Products | 1 | 2021 | 151 | 0.660 |
Why?
|
| Bone Diseases, Metabolic | 1 | 2019 | 33 | 0.660 |
Why?
|
| Intestinal Neoplasms | 1 | 2019 | 64 | 0.650 |
Why?
|
| Bariatric Surgery | 1 | 2021 | 195 | 0.650 |
Why?
|
| Osteoporosis | 2 | 2019 | 122 | 0.650 |
Why?
|
| Central Venous Catheters | 1 | 2019 | 22 | 0.640 |
Why?
|
| Organ Transplantation | 1 | 2022 | 275 | 0.640 |
Why?
|
| Organometallic Compounds | 1 | 2019 | 134 | 0.640 |
Why?
|
| Nutritional Sciences | 1 | 2018 | 13 | 0.610 |
Why?
|
| Lymphatic Metastasis | 1 | 2019 | 502 | 0.590 |
Why?
|
| Osteogenesis | 1 | 2019 | 255 | 0.590 |
Why?
|
| Gastroenterologists | 1 | 2018 | 31 | 0.590 |
Why?
|
| Betacoronavirus | 1 | 2020 | 261 | 0.580 |
Why?
|
| Tumor Necrosis Factor-alpha | 5 | 2019 | 699 | 0.570 |
Why?
|
| Intensive Care Units | 1 | 2020 | 395 | 0.560 |
Why?
|
| Diet | 1 | 2020 | 442 | 0.560 |
Why?
|
| Female | 40 | 2024 | 46011 | 0.560 |
Why?
|
| Middle Aged | 27 | 2024 | 25863 | 0.550 |
Why?
|
| Fellowships and Scholarships | 1 | 2018 | 121 | 0.550 |
Why?
|
| Male | 37 | 2024 | 42251 | 0.550 |
Why?
|
| Mediastinal Diseases | 1 | 2016 | 22 | 0.540 |
Why?
|
| Antibodies, Monoclonal | 7 | 2021 | 1400 | 0.540 |
Why?
|
| Granuloma | 1 | 2016 | 65 | 0.530 |
Why?
|
| Celiac Disease | 1 | 2019 | 213 | 0.530 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 319 | 0.510 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 304 | 0.500 |
Why?
|
| Aged | 19 | 2024 | 19077 | 0.490 |
Why?
|
| Colonoscopy | 6 | 2024 | 279 | 0.490 |
Why?
|
| Deglutition Disorders | 1 | 2016 | 119 | 0.490 |
Why?
|
| Adult | 24 | 2024 | 26507 | 0.480 |
Why?
|
| Ileitis | 1 | 2014 | 7 | 0.470 |
Why?
|
| Education, Medical, Graduate | 1 | 2018 | 390 | 0.450 |
Why?
|
| Antibodies, Monoclonal, Humanized | 5 | 2019 | 967 | 0.440 |
Why?
|
| Gastrointestinal Neoplasms | 3 | 2018 | 111 | 0.440 |
Why?
|
| Cystic Fibrosis | 3 | 2018 | 115 | 0.430 |
Why?
|
| Aspartate Aminotransferases | 2 | 2024 | 74 | 0.420 |
Why?
|
| Colorectal Neoplasms | 4 | 2023 | 981 | 0.410 |
Why?
|
| Treatment Outcome | 17 | 2024 | 8203 | 0.390 |
Why?
|
| Diagnosis, Differential | 3 | 2020 | 1591 | 0.350 |
Why?
|
| Calcineurin Inhibitors | 2 | 2021 | 53 | 0.340 |
Why?
|
| Pharmaceutical Preparations | 2 | 2021 | 91 | 0.340 |
Why?
|
| Severity of Illness Index | 7 | 2021 | 1837 | 0.340 |
Why?
|
| Fibrosis | 2 | 2021 | 234 | 0.330 |
Why?
|
| Abdominal Pain | 2 | 2020 | 138 | 0.320 |
Why?
|
| Liver Cirrhosis | 3 | 2021 | 254 | 0.320 |
Why?
|
| Antirheumatic Agents | 2 | 2020 | 55 | 0.320 |
Why?
|
| Weight Loss | 3 | 2019 | 225 | 0.300 |
Why?
|
| Mesentery | 2 | 2019 | 45 | 0.300 |
Why?
|
| Biopsy | 3 | 2021 | 1182 | 0.300 |
Why?
|
| Cholangitis, Sclerosing | 2 | 2018 | 51 | 0.290 |
Why?
|
| Inpatients | 3 | 2021 | 310 | 0.280 |
Why?
|
| Gastrointestinal Diseases | 2 | 2017 | 151 | 0.250 |
Why?
|
| Colectomy | 2 | 2024 | 172 | 0.250 |
Why?
|
| Prospective Studies | 5 | 2021 | 4273 | 0.250 |
Why?
|
| Colitis, Microscopic | 1 | 2024 | 6 | 0.240 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 3 | 2024 | 242 | 0.240 |
Why?
|
| Budesonide | 1 | 2024 | 46 | 0.230 |
Why?
|
| Lung Diseases, Interstitial | 2 | 2020 | 260 | 0.230 |
Why?
|
| Alanine Transaminase | 1 | 2024 | 71 | 0.230 |
Why?
|
| Risk Assessment | 5 | 2019 | 2290 | 0.230 |
Why?
|
| Bilirubin | 1 | 2024 | 129 | 0.230 |
Why?
|
| Adenomatous Polyps | 1 | 2023 | 13 | 0.230 |
Why?
|
| Cohort Studies | 4 | 2024 | 2863 | 0.220 |
Why?
|
| Adolescent, Hospitalized | 1 | 2022 | 1 | 0.220 |
Why?
|
| Diarrhea | 2 | 2014 | 182 | 0.220 |
Why?
|
| Gastrostomy | 1 | 2023 | 69 | 0.210 |
Why?
|
| ROC Curve | 3 | 2021 | 781 | 0.210 |
Why?
|
| Ulcer | 1 | 2022 | 37 | 0.210 |
Why?
|
| Vaccines, Synthetic | 1 | 2022 | 55 | 0.210 |
Why?
|
| Hemoglobins | 1 | 2023 | 192 | 0.210 |
Why?
|
| Diverticulum | 2 | 2019 | 45 | 0.210 |
Why?
|
| Cytomegalovirus | 1 | 2022 | 76 | 0.200 |
Why?
|
| Polymerase Chain Reaction | 2 | 2022 | 921 | 0.200 |
Why?
|
| Adolescent | 11 | 2022 | 9237 | 0.200 |
Why?
|
| Young Adult | 10 | 2019 | 6288 | 0.200 |
Why?
|
| Platelet Count | 1 | 2021 | 93 | 0.190 |
Why?
|
| Hospitals | 1 | 2024 | 299 | 0.190 |
Why?
|
| Adenoma | 1 | 2023 | 246 | 0.190 |
Why?
|
| Adenomatous Polyposis Coli | 1 | 2021 | 39 | 0.190 |
Why?
|
| Double-Balloon Enteroscopy | 1 | 2021 | 11 | 0.190 |
Why?
|
| Prognosis | 5 | 2022 | 3773 | 0.190 |
Why?
|
| Gastrointestinal Tract | 1 | 2023 | 191 | 0.190 |
Why?
|
| Propensity Score | 1 | 2021 | 147 | 0.190 |
Why?
|
| Nutritional Status | 1 | 2021 | 80 | 0.190 |
Why?
|
| Antibodies, Viral | 1 | 2022 | 309 | 0.180 |
Why?
|
| Enteral Nutrition | 1 | 2021 | 102 | 0.180 |
Why?
|
| Antiplatyhelmintic Agents | 1 | 2020 | 5 | 0.180 |
Why?
|
| Vitamin D | 2 | 2021 | 268 | 0.180 |
Why?
|
| Life Cycle Stages | 1 | 2020 | 15 | 0.180 |
Why?
|
| Biomarkers | 4 | 2021 | 1755 | 0.180 |
Why?
|
| Colonic Polyps | 1 | 2021 | 132 | 0.180 |
Why?
|
| Interleukin-23 | 1 | 2020 | 57 | 0.180 |
Why?
|
| Warfarin | 1 | 2020 | 104 | 0.180 |
Why?
|
| Lubricants | 1 | 2019 | 7 | 0.170 |
Why?
|
| Panniculitis, Peritoneal | 1 | 2019 | 4 | 0.170 |
Why?
|
| Laxatives | 1 | 2019 | 13 | 0.170 |
Why?
|
| Interleukin-12 | 1 | 2020 | 109 | 0.170 |
Why?
|
| Prevalence | 5 | 2021 | 1240 | 0.170 |
Why?
|
| Aged, 80 and over | 7 | 2023 | 6777 | 0.170 |
Why?
|
| Double-Blind Method | 1 | 2024 | 1714 | 0.170 |
Why?
|
| Cyclosporine | 2 | 2018 | 237 | 0.170 |
Why?
|
| Vitamin D Deficiency | 1 | 2021 | 103 | 0.170 |
Why?
|
| Mesenteric Artery, Superior | 1 | 2019 | 19 | 0.170 |
Why?
|
| Travel | 1 | 2020 | 71 | 0.170 |
Why?
|
| Mesenteric Veins | 1 | 2019 | 33 | 0.170 |
Why?
|
| Respiratory Tract Infections | 1 | 2020 | 106 | 0.170 |
Why?
|
| Drug Substitution | 1 | 2019 | 26 | 0.170 |
Why?
|
| Tacrolimus | 2 | 2018 | 369 | 0.170 |
Why?
|
| Radionuclide Imaging | 1 | 2019 | 221 | 0.170 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2020 | 169 | 0.160 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2020 | 128 | 0.160 |
Why?
|
| Diet, Gluten-Free | 1 | 2019 | 57 | 0.160 |
Why?
|
| Logistic Models | 3 | 2018 | 1212 | 0.160 |
Why?
|
| Hyperparathyroidism, Secondary | 1 | 2019 | 68 | 0.160 |
Why?
|
| Odds Ratio | 6 | 2017 | 684 | 0.160 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 2 | 2018 | 202 | 0.160 |
Why?
|
| Osteoporotic Fractures | 1 | 2019 | 43 | 0.160 |
Why?
|
| Interleukin-17 | 1 | 2019 | 105 | 0.160 |
Why?
|
| Ileum | 1 | 2019 | 160 | 0.160 |
Why?
|
| Ribotyping | 2 | 2015 | 11 | 0.150 |
Why?
|
| Bone Density | 1 | 2019 | 209 | 0.150 |
Why?
|
| Incidence | 5 | 2021 | 1592 | 0.150 |
Why?
|
| Fractures, Bone | 1 | 2019 | 127 | 0.150 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2019 | 266 | 0.150 |
Why?
|
| Survival Rate | 1 | 2022 | 1889 | 0.150 |
Why?
|
| Paraneoplastic Syndromes | 1 | 2017 | 16 | 0.150 |
Why?
|
| Equipment Design | 1 | 2019 | 415 | 0.150 |
Why?
|
| Pandemics | 2 | 2020 | 771 | 0.150 |
Why?
|
| CTLA-4 Antigen | 1 | 2017 | 139 | 0.140 |
Why?
|
| Early Detection of Cancer | 2 | 2023 | 415 | 0.140 |
Why?
|
| Carcinoma, Small Cell | 1 | 2017 | 133 | 0.140 |
Why?
|
| Glucocorticoids | 2 | 2020 | 357 | 0.140 |
Why?
|
| Itraconazole | 1 | 2016 | 11 | 0.140 |
Why?
|
| Predictive Value of Tests | 2 | 2019 | 1715 | 0.140 |
Why?
|
| Paracentesis | 1 | 2016 | 10 | 0.140 |
Why?
|
| Ambulatory Care | 1 | 2018 | 187 | 0.140 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2017 | 170 | 0.130 |
Why?
|
| Drug Therapy, Combination | 1 | 2018 | 783 | 0.130 |
Why?
|
| Small Cell Lung Carcinoma | 1 | 2017 | 103 | 0.130 |
Why?
|
| Ascites | 1 | 2016 | 56 | 0.130 |
Why?
|
| Atrial Fibrillation | 1 | 2020 | 350 | 0.130 |
Why?
|
| Endoscopy | 1 | 2019 | 348 | 0.130 |
Why?
|
| Bronchoscopy | 1 | 2017 | 159 | 0.130 |
Why?
|
| Wound Healing | 1 | 2018 | 359 | 0.130 |
Why?
|
| Lymph Nodes | 1 | 2019 | 548 | 0.130 |
Why?
|
| Antifungal Agents | 1 | 2016 | 119 | 0.130 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2018 | 219 | 0.130 |
Why?
|
| Registries | 1 | 2020 | 778 | 0.130 |
Why?
|
| Women's Health | 1 | 2016 | 102 | 0.130 |
Why?
|
| Age Factors | 5 | 2018 | 1867 | 0.130 |
Why?
|
| Botulinum Toxins | 1 | 2015 | 17 | 0.130 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2017 | 195 | 0.130 |
Why?
|
| Analgesics, Opioid | 1 | 2019 | 442 | 0.120 |
Why?
|
| Pregnancy Outcome | 1 | 2016 | 253 | 0.120 |
Why?
|
| Histiocytosis, Langerhans-Cell | 1 | 2014 | 24 | 0.120 |
Why?
|
| Remission Induction | 3 | 2024 | 740 | 0.120 |
Why?
|
| Intestinal Obstruction | 1 | 2015 | 88 | 0.120 |
Why?
|
| Calcium | 1 | 2019 | 1172 | 0.120 |
Why?
|
| History, 18th Century | 1 | 2014 | 21 | 0.120 |
Why?
|
| History, 19th Century | 1 | 2014 | 56 | 0.120 |
Why?
|
| Pregnancy Complications | 1 | 2016 | 345 | 0.110 |
Why?
|
| Erythrocyte Transfusion | 1 | 2014 | 72 | 0.110 |
Why?
|
| Feces | 1 | 2015 | 327 | 0.110 |
Why?
|
| Calcitonin | 1 | 2013 | 38 | 0.110 |
Why?
|
| Curriculum | 1 | 2018 | 567 | 0.110 |
Why?
|
| Tertiary Care Centers | 1 | 2013 | 106 | 0.110 |
Why?
|
| Frail Elderly | 1 | 2013 | 82 | 0.110 |
Why?
|
| Animals | 4 | 2020 | 27317 | 0.110 |
Why?
|
| Primary Health Care | 1 | 2016 | 351 | 0.100 |
Why?
|
| Protein Precursors | 1 | 2013 | 140 | 0.100 |
Why?
|
| History, 20th Century | 1 | 2014 | 310 | 0.100 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2019 | 1363 | 0.100 |
Why?
|
| Immunotherapy | 1 | 2017 | 669 | 0.100 |
Why?
|
| Kidney Transplantation | 1 | 2018 | 849 | 0.100 |
Why?
|
| Motor Activity | 1 | 2013 | 327 | 0.090 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2020 | 833 | 0.090 |
Why?
|
| Child | 6 | 2022 | 7149 | 0.090 |
Why?
|
| Postoperative Period | 2 | 2021 | 301 | 0.090 |
Why?
|
| CD40 Antigens | 1 | 2009 | 44 | 0.090 |
Why?
|
| Length of Stay | 3 | 2021 | 732 | 0.090 |
Why?
|
| Databases, Factual | 3 | 2019 | 850 | 0.080 |
Why?
|
| Liver Transplantation | 1 | 2016 | 1177 | 0.080 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2019 | 2657 | 0.080 |
Why?
|
| Interleukin-2 | 1 | 2009 | 251 | 0.080 |
Why?
|
| Liver Function Tests | 2 | 2020 | 92 | 0.080 |
Why?
|
| Recurrence | 3 | 2021 | 1140 | 0.080 |
Why?
|
| Time Factors | 4 | 2018 | 5320 | 0.080 |
Why?
|
| Cell Proliferation | 1 | 2014 | 1650 | 0.080 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2020 | 3443 | 0.080 |
Why?
|
| T-Lymphocytes | 1 | 2014 | 1223 | 0.080 |
Why?
|
| Antibodies | 1 | 2009 | 353 | 0.070 |
Why?
|
| Interleukin-6 | 2 | 2020 | 261 | 0.070 |
Why?
|
| Colitis, Collagenous | 1 | 2024 | 2 | 0.060 |
Why?
|
| Colitis, Lymphocytic | 1 | 2024 | 4 | 0.060 |
Why?
|
| Lung Neoplasms | 1 | 2017 | 2347 | 0.060 |
Why?
|
| Proton Pump Inhibitors | 1 | 2024 | 34 | 0.060 |
Why?
|
| Child, Preschool | 3 | 2018 | 3717 | 0.060 |
Why?
|
| Intubation, Gastrointestinal | 1 | 2023 | 31 | 0.060 |
Why?
|
| Michigan | 2 | 2013 | 53 | 0.050 |
Why?
|
| Disease Progression | 2 | 2018 | 1488 | 0.050 |
Why?
|
| Hospital Mortality | 2 | 2016 | 386 | 0.050 |
Why?
|
| United States | 3 | 2022 | 6955 | 0.050 |
Why?
|
| Pregnancy | 2 | 2020 | 3009 | 0.050 |
Why?
|
| Piperidines | 1 | 2022 | 164 | 0.050 |
Why?
|
| Diverticulum, Esophageal | 1 | 1981 | 6 | 0.050 |
Why?
|
| Dabigatran | 1 | 2020 | 25 | 0.050 |
Why?
|
| Cytoreduction Surgical Procedures | 1 | 2021 | 76 | 0.050 |
Why?
|
| Morphinans | 1 | 2019 | 4 | 0.040 |
Why?
|
| Cholestasis | 1 | 2020 | 45 | 0.040 |
Why?
|
| Bile Acids and Salts | 1 | 2020 | 66 | 0.040 |
Why?
|
| Steroids | 1 | 2020 | 174 | 0.040 |
Why?
|
| Administration, Oral | 1 | 2020 | 682 | 0.040 |
Why?
|
| Organ Size | 1 | 2020 | 369 | 0.040 |
Why?
|
| Risk | 1 | 2020 | 657 | 0.040 |
Why?
|
| Spinal Fractures | 1 | 2019 | 77 | 0.040 |
Why?
|
| Dermatologic Agents | 1 | 2019 | 73 | 0.040 |
Why?
|
| Patient Protection and Affordable Care Act | 1 | 2019 | 67 | 0.040 |
Why?
|
| Naltrexone | 1 | 2019 | 136 | 0.040 |
Why?
|
| Narcotic Antagonists | 1 | 2019 | 157 | 0.040 |
Why?
|
| Life Expectancy | 1 | 2018 | 89 | 0.040 |
Why?
|
| Age Distribution | 1 | 2018 | 200 | 0.040 |
Why?
|
| Biological Therapy | 1 | 2018 | 47 | 0.040 |
Why?
|
| Databases, Bibliographic | 1 | 2017 | 17 | 0.040 |
Why?
|
| Polyethylene Glycols | 1 | 2019 | 358 | 0.040 |
Why?
|
| Anticoagulants | 1 | 2020 | 426 | 0.040 |
Why?
|
| Data Mining | 1 | 2017 | 42 | 0.040 |
Why?
|
| Hepatitis, Chronic | 1 | 2016 | 5 | 0.040 |
Why?
|
| C-Reactive Protein | 1 | 2018 | 192 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2019 | 859 | 0.040 |
Why?
|
| Colon | 1 | 2020 | 509 | 0.030 |
Why?
|
| Induction Chemotherapy | 1 | 2017 | 151 | 0.030 |
Why?
|
| Infant | 2 | 2014 | 3147 | 0.030 |
Why?
|
| Immunosuppressive Agents | 1 | 2021 | 975 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2018 | 894 | 0.030 |
Why?
|
| Directive Counseling | 1 | 2016 | 35 | 0.030 |
Why?
|
| Patient Discharge | 1 | 2019 | 320 | 0.030 |
Why?
|
| Cost Savings | 1 | 2016 | 69 | 0.030 |
Why?
|
| Risk Reduction Behavior | 1 | 2016 | 96 | 0.030 |
Why?
|
| Vomiting | 1 | 2017 | 194 | 0.030 |
Why?
|
| Population Surveillance | 1 | 2016 | 216 | 0.030 |
Why?
|
| Hospital Costs | 1 | 2016 | 107 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2018 | 988 | 0.030 |
Why?
|
| Anti-Bacterial Agents | 1 | 2021 | 786 | 0.030 |
Why?
|
| Sex Factors | 1 | 2018 | 1063 | 0.030 |
Why?
|
| Intestinal Mucosa | 1 | 2020 | 805 | 0.030 |
Why?
|
| Patient Safety | 1 | 2017 | 216 | 0.030 |
Why?
|
| Cladribine | 1 | 2014 | 35 | 0.030 |
Why?
|
| Mice, Knockout | 1 | 2020 | 1990 | 0.030 |
Why?
|
| Immunoenzyme Techniques | 1 | 2015 | 306 | 0.030 |
Why?
|
| Phytohemagglutinins | 1 | 2014 | 22 | 0.030 |
Why?
|
| Quality Indicators, Health Care | 1 | 2016 | 146 | 0.030 |
Why?
|
| Evidence-Based Medicine | 1 | 2017 | 433 | 0.030 |
Why?
|
| Antigens, CD1 | 1 | 2014 | 37 | 0.030 |
Why?
|
| CD3 Complex | 1 | 2014 | 134 | 0.030 |
Why?
|
| Blood Preservation | 1 | 2014 | 10 | 0.030 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2017 | 345 | 0.030 |
Why?
|
| Interleukin-1beta | 1 | 2014 | 82 | 0.030 |
Why?
|
| CD28 Antigens | 1 | 2014 | 90 | 0.030 |
Why?
|
| Gastroenteritis | 1 | 2014 | 26 | 0.030 |
Why?
|
| Lung Transplantation | 1 | 2018 | 290 | 0.030 |
Why?
|
| Drug Resistance | 1 | 2014 | 232 | 0.030 |
Why?
|
| Genetic Markers | 1 | 2014 | 478 | 0.030 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2014 | 146 | 0.030 |
Why?
|
| Infant, Newborn | 1 | 2020 | 2476 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 1 | 2016 | 461 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2016 | 948 | 0.030 |
Why?
|
| Inflammation Mediators | 1 | 2014 | 153 | 0.030 |
Why?
|
| Chicago | 1 | 2018 | 1423 | 0.030 |
Why?
|
| Confidence Intervals | 1 | 2013 | 225 | 0.030 |
Why?
|
| Adaptive Immunity | 1 | 2014 | 167 | 0.030 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2014 | 181 | 0.030 |
Why?
|
| DNA Mutational Analysis | 1 | 2014 | 529 | 0.030 |
Why?
|
| Calcitonin Gene-Related Peptide | 1 | 2013 | 40 | 0.030 |
Why?
|
| Cross-Over Studies | 1 | 2014 | 389 | 0.030 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2020 | 504 | 0.030 |
Why?
|
| Lipopolysaccharides | 1 | 2014 | 293 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2020 | 3209 | 0.030 |
Why?
|
| Positron-Emission Tomography | 1 | 2014 | 336 | 0.030 |
Why?
|
| Mice | 2 | 2020 | 11737 | 0.020 |
Why?
|
| Models, Statistical | 1 | 2015 | 575 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2020 | 1975 | 0.020 |
Why?
|
| Immunity, Innate | 1 | 2014 | 429 | 0.020 |
Why?
|
| Postoperative Complications | 1 | 2021 | 2275 | 0.020 |
Why?
|
| Macrophage Inflammatory Proteins | 1 | 2009 | 9 | 0.020 |
Why?
|
| Chemokine CCL5 | 1 | 2009 | 16 | 0.020 |
Why?
|
| Chemokine CXCL9 | 1 | 2009 | 8 | 0.020 |
Why?
|
| Receptors, Cytokine | 1 | 2009 | 28 | 0.020 |
Why?
|
| Arginase | 1 | 2009 | 16 | 0.020 |
Why?
|
| Receptors, CCR2 | 1 | 2009 | 34 | 0.020 |
Why?
|
| Chemokines, CC | 1 | 2009 | 36 | 0.020 |
Why?
|
| Chemokines | 1 | 2009 | 74 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2014 | 1855 | 0.020 |
Why?
|
| Drug Synergism | 1 | 2009 | 306 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2014 | 2880 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2020 | 3373 | 0.020 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2009 | 131 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 1 | 2009 | 1087 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2012 | 1706 | 0.020 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2009 | 443 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2013 | 3657 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2012 | 2752 | 0.020 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2009 | 594 | 0.020 |
Why?
|
| Mutation | 1 | 2014 | 4132 | 0.010 |
Why?
|